Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 11, Issue 7, Pages 617
Publisher
MDPI AG
Online
2021-06-30
DOI
10.3390/jpm11070617
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects
- (2021) Hang-Xing Huang et al. XENOBIOTICA
- CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review
- (2019) Palden Wangyel Dorji et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Developmental Changes in Pharmacokinetics and Pharmacodynamics
- (2018) John van den Anker et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro
- (2014) Pei-Pei Pan et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Genetic Polymorphisms of Metabolic Enzymes and the Pharmacokinetics of Indapamide in Taiwanese Subjects
- (2013) Teng-Hsu Wang et al. AAPS Journal
- Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174
- (2012) Jung-Woo Bae et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
- (2011) Jung-woo Bae et al. ACTA PHARMACOLOGICA SINICA
- Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats
- (2011) Si-hyung Yang et al. ACTA PHARMACOLOGICA SINICA
- CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
- (2011) Chang-Ik Choi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetic evaluation of losartan
- (2011) Michel Burnier et al. Expert Opinion on Drug Metabolism & Toxicology
- Meta-analyses of small numbers of trials often agree with longer-term results
- (2010) Peter Herbison et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cytochrome P450 2C9-CYP2C9
- (2010) Derek Van Booven et al. Pharmacogenetics and Genomics
- Polymorphism of human cytochrome P450 enzymes and its clinical impact
- (2009) Shu-Feng Zhou et al. DRUG METABOLISM REVIEWS
- Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers
- (2009) Yang Han et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of theCYP2C9*13allele on the pharmacokinetics of losartan in healthy male subjects
- (2009) Z. Li et al. XENOBIOTICA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- The Effect of Bucolome, a CYP2C9 Inhibitor, on the Pharmacokinetics of Losartan
- (2008) Mariko Kobayashi et al. Drug Metabolism and Pharmacokinetics
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started